Aarti Drugs Ltd.
Snapshot View

420.00 +6.00 ▲1.5%

20 May 2022, 04:01:00 PM
Volume: 7,398

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.aartidrugs.com
Market Cap 3,889.20 Cr.
Enterprise Value(EV) 4,427.54 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 22.14 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 18.97 Trailing Twelve Months Ending 2022-03
Industry PE 29.26 Trailing Twelve Months Ending 2022-03
Book Value / Share 111.92 Trailing Twelve Months Ending 2022-03
Price to Book Value 3.75 Calculated using Price: 420.00
Dividend Yield 0.60 Period Ending 2021-03
No. of Shares Subscribed 9.26 Cr. 92,600,000 Shares
FaceValue 10
Company Profile

Aarti Drugs (ADL), incorporated in 1984, is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries.

ADL manufactures drugs in therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, anti-cholinergic, sedatives, anti-depressant, anti-diarrhea and anti-inflammatory. The company’s manufacturing facilities are located at Tarapur and Sarigam. The drug major has received ISO 9001:2000 certifications for quality management.

Products

API- ADL manufactures active pharmaceuticals ingredients (API) and steroids. Under API, it manufactures products such as aceclofenac, clopidogrel bisulphate, ketoconazole, metformin HCl, hydroxyzine pomoate, ketoconazole, irbesartan and many more. The company manufactures steroids such as hydrocortisone sodium succinate sterile, hydrocortisone acetate, hydrocortisone and hemisuccinate.

Pharma Intermediates- The company manufactures pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine

Speciality Chemicals- Under this, the company manufactures products such as benzene sulphonyl chloride, benzene sulphonamide, diphenyl sulphone, N-ethyl toluene sulphonamide, ethyl toluene sulphonate, para chloro benzene sulphonamide, benzene sulfonyl hydrazide and many more.

The company’s R&D centre at Turbhe near Mumbai, focuses on developing new value added molecules. This facility is recognised by Department of Science and Industrial Research and Government of India.

The company also undertakes contract manufacturing for its customers.

ADL's products are exported to over 85 countries across the globe. It has received Export House Status recognition of from Government of India. The company has clientele namely Sanofi-Aventis, Merck, Teva , Searle, Pfizer, Bayer and Clariant to name a few.

New Development

Aarti Drugs' R&D programs are currently focused on new products amongest non-steroidal NSAID compounds, antiparasitic, calciun antagonist, antianginal, antidiabetics, antdepressant and many more. The company has also planned to work on speciality chemicals and agro chemicals.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.45%
1 Week
-1.07%
1 Month
-13.12%
3 Month
-15.89%
6 Month
-21.01%
1 Year
-44.48%
2 Year
+110.79%
5 Year
+220.0%
10 Year
+3081.82%
9 years 2010-03 2011-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 21.09 15.18 32.78 20.65 21.60 19.24 17.97 23.65 35.81
Return on Capital Employed (%) 20.30 13.12 23.93 18.33 18.50 17.31 17.01 21.39 34.52
Return on Assets (%) 6.92 4.99 10.13 6.53 7.13 6.38 6.31 9.33 16.78

Balance Sheet View Details

Particulars 9 years 2011-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 163 308 357 400 455 543 652 913 1,036
Non Curr. Liab. 290 211 244 297 312 321 301 257 232
Curr. Liab. 70 483 501 494 622 591 623 595 940
Minority Int. 0 0
Equity & Liab. 523 1,002 1,102 1,191 1,389 1,455 1,577 1,766 2,208
Non Curr. Assets 264 476 537 620 653 671 673 709 815
Curr. Assets 260 526 565 571 737 784 904 1,057 1,393
Misc. Exp. not W/O
Total Assets 523 1,002 1,102 1,191 1,389 1,455 1,577 1,766 2,208

Profit Loss View Details

Particulars 10 years 2010-03 Rs. Cr. 2011-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 479 501 1,097 1,140 1,195 1,244 1,561 1,806 2,155 2,489
Other Income 1 0 1 4 1 2 1 5 11
Total Income 479 501 1,098 1,140 1,199 1,245 1,563 1,808 2,159 2,500
Total Expenditure -396 -432 -925 -960 -1,005 -1,042 -1,350 -1,541 -1,714 -2,159
PBIDT 83 69 173 180 194 203 213 267 445 341
Interest -19 -17 -42 -48 -40 -38 -44 -37 -26 -21
Depreciation -17 -19 -31 -37 -38 -40 -43 -49 -50 -50
Taxation -19 -10 -22 -27 -34 -42 -41 -44 -89 -65
Exceptional Items 4 4 0
PAT 28 24 77 69 82 82 90 141 280 205
Minority Interest 0 0 0
Share Associate 0 0
Other Related Items
Consolidated Net Profit 28 24 77 69 82 82 90 141 280 205
Adjusted EPS 3 2 8 7 9 9 10 15 30 22

Cash Flow View Details

Particulars 8 years 2011-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 21 105 133 175 70 143 251 155
Cash Fr. Inv. -76 -107 -99 -107 -74 -62 -33 -72
Cash Fr. Finan. 53 1 -33 -68 4 -80 -215 -81
Net Change -3 -1 1 0 0 1 2 2
Cash & Cash Eqvt 5 4 5 3 3 5 7 9

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 61.44 60.51 60.21 60.20 60.20 60.14 60.12 59.99 59.83
Public 38.56 39.49 39.79 39.80 39.80 39.86 39.88 40.01 40.17
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 16 May 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find attached herewith transcript of Q4 FY22 Earning Conference call.
Fri, 13 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company AARTI DRUGS LTD.
2 CIN NO. L37060MH1984PLC055433
3 Report filed for FY 2021-2022
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* FY 2021-22 2022-23
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)FY 2020-21 2021-22
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-Rushikesh Deole
Designation :-Company Secretary and Compliance Officer
Name of the Chief Financial Officer :- Adhish P Patil
Designation : -Chief Financial Officer

Date: 13/05/2022

Tue, 10 May 2022
Recording Of Conference Call
In continuation to our letter dated May 5 2022 regarding intimation of Investors/ Analyst conference call on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2022 we would like to inform you that the audio recording of the said call has been uploaded on the Companys website. This can be accessed via the following link. Link: https://www.aartidrugs.co.in/concalls-transcript/

Technical Scans View Details

Fri, 20 May 2022
Opening at Low Opening at Low
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Decrease 6 Months High Decrease 6 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%